Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions.
Splenic marginal zone lymphoma (SMZL) is a rare type of B-cell lymphoma that affects the spleen, bone marrow, and sometimes the blood. It is a low-grade neoplasm that originates from the germinal centers of the splenic white pulp. The neoplastic cells are small lymphocytes and larger transformed lymphoblasts that invade the mantle and marginal zones of the spleen and erode its normal architecture. SMZL may be associated with hepatitis C virus infection in some cases. The diagnosis of SMZL requires the presence of splenomegaly and splenic histology. The bone marrow may show nodular infiltration by neoplastic cells with marginal zone differentiation. Peripheral blood may contain villous lymphocytes with plasmacytoid features. SMZL is an indolent disease that may not require immediate treatment unless symptoms or cytopenias are present. Rituximab-based therapies are effective in most patients, and novel agents are being investigated for relapsed or refractory cases.
The Splenic Marginal Zone B-Cell Lymphoma drugs in development market research report provide comprehensive information on the therapeutics under development for Splenic Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Splenic Marginal Zone B-Cell Lymphoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Splenic Marginal Zone B-Cell Lymphoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Splenic Marginal Zone B-Cell Lymphoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Splenic Marginal Zone B-Cell Lymphoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Splenic Marginal Zone B-Cell Lymphoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAmgen Inc
Antengene Corp Ltd
AstraZeneca Plc
Aurigene Oncology Ltd
BeiGene Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
CoImmune Inc
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
General Hospital of the People's Liberation Army
Hutchison MediPharma Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Institute of Biomedical Research of Salamanca
Johnson & Johnson
Medical College of Wisconsin
MorphoSys AG
Nanjing Sanhome Pharmaceutical Co Ltd
Oncternal Therapeutics
Secura Bio Inc
Shanghai Henlius Biotech Inc
Swedish Orphan Biovitrum AB
SymBio Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
UNC Lineberger Comprehensive Cancer Center
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Splenic Marginal Zone B-Cell Lymphoma reports